Ignite Creation Date:
2024-05-06 @ 9:43 AM
Last Modification Date:
2024-10-26 @ 12:18 PM
Study NCT ID:
NCT03052608
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2017-01-20
Brief Title:
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Sponsor:
Pfizer
Organization:
Pfizer
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-04-27
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2028-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2017-01-20
First Submit QC Date:
February 9 2017
Study First Post Date:
2017-02-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2021-04-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-24
Last Update Post Date:
2024-06-26
Last Update Post Date Type:
ACTUAL